Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04108195
Title A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC

multiple myeloma


Daratumumab + Teclistamab

Daratumumab + Talquetamab

Age Groups: senior | adult
Covered Countries USA | ESP | DEU | CAN

No variant requirements are available.